WT1 is an inclusion criterion in 7 clinical trials for acute myeloid leukemia, of which 6 are open and 1 is closed. Of the trials that contain WT1 status and acute myeloid leukemia as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (2 open), and 1 is phase 3 (1 open) [4].

WT1 is an inclusion criterion in 2 clinical trials for fallopian tube carcinoma, of which 2 are open and 0 are closed. Of the trials that contain WT1 status and fallopian tube carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

WT1 is an inclusion criterion in 2 clinical trials for malignant solid tumor, of which 2 are open and 0 are closed. Of the trials that contain WT1 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

WT1 is an inclusion criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain WT1 status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) and 1 is no phase specified (1 open) [4].

WT1 is an inclusion criterion in 2 clinical trials for myelodysplastic syndromes, of which 2 are open and 0 are closed. Of the trials that contain WT1 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

WT1 is an inclusion criterion in 2 clinical trials for non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain WT1 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

WT1 is an inclusion criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain WT1 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

WT1 is an inclusion criterion in 2 clinical trials for primary peritoneal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain WT1 status and primary peritoneal carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

WT1 is an inclusion criterion in 1 clinical trial for acute biphenotypic leukemia, of which 1 is open and 0 are closed. Of the trial that contains WT1 status and acute biphenotypic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

WT1 is an inclusion criterion in 1 clinical trial for acute erythroid leukemia, of which 1 is open and 0 are closed. Of the trial that contains WT1 status and acute erythroid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

WT1 is an inclusion criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains WT1 status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

WT1 is an inclusion criterion in 1 clinical trial for acute megakaryoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains WT1 status and acute megakaryoblastic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

WT1 is an inclusion criterion in 1 clinical trial for acute undifferentiated leukemia, of which 1 is open and 0 are closed. Of the trial that contains WT1 status and acute undifferentiated leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

WT1 is an inclusion criterion in 1 clinical trial for chronic myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains WT1 status and chronic myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

WT1 is an inclusion criterion in 1 clinical trial for desmoplastic small round cell tumor, of which 1 is open and 0 are closed. Of the trial that contains WT1 status and desmoplastic small round cell tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

WT1 is an inclusion criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains WT1 status and endometrial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

WT1 is an inclusion criterion in 1 clinical trial for hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains WT1 status and hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

WT1 is an inclusion criterion in 1 clinical trial for juvenile myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains WT1 status and juvenile myelomonocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

WT1 is an inclusion criterion in 1 clinical trial for malignant pleural mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains WT1 status and malignant pleural mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [4].

WT1 is an inclusion criterion in 1 clinical trial for mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains WT1 status and mesothelioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

WT1 is an inclusion criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains WT1 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (1 open) [4].

WT1 is an inclusion criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains WT1 status and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

WT1 is an inclusion criterion in 1 clinical trial for myeloid sarcoma, of which 1 is open and 0 are closed. Of the trial that contains WT1 status and myeloid sarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

WT1 is an inclusion criterion in 1 clinical trial for natural killer cell lymphoblastic leukemia/lymphoma, of which 1 is open and 0 are closed. Of the trial that contains WT1 status and natural killer cell lymphoblastic leukemia/lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

WT1 is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains WT1 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

WT1 is an inclusion criterion in 1 clinical trial for secondary acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains WT1 status and secondary acute myeloid leukemia as inclusion criteria, 1 is phase 3 (1 open) [4].

WT1 is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains WT1 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open) [4].